How is MDS graded and what does the grade mean

How MDS is Graded and What It Means

MDS is graded using risk stratification systems that help doctors predict how the disease might progress and guide treatment decisions. Think of these systems as tools that combine multiple factors to create a "risk score" — similar to how credit scores predict financial risk.

The Main Grading Systems

According to the NCCN Guidelines for Myelodysplastic Syndromes, doctors use several scoring systems, with the IPSS-R (Revised International Prognostic Scoring System) being the most commonly used today.

IPSS-R Risk Categories

The IPSS-R divides patients into five risk groups:

• Very-Low Risk
• Low Risk
• Intermediate Risk
• High Risk
• Very-High Risk

There's also a newer system called IPSS-M (available through a web calculator at mds-risk-model.com) that incorporates genetic mutations for even more precise risk assessment.

What Factors Go Into the Grade?

Your MDS grade is determined by combining several key pieces of information:

1. Blast Percentage

• The percentage of immature blood cells (blasts) in your bone marrow
• Higher percentages indicate more advanced disease

2. Cytogenetics (Chromosome Abnormalities)

• Specific chromosome changes detected in your bone marrow cells
• Some changes are favorable (like deletion 5q), while others are unfavorable (like complex karyotypes)

3. Genetic Mutations

• According to NCCN Guidelines, doctors look for mutations in genes frequently mutated in MDS, including:
  • TP53 — associated with poor prognosis
  • SF3B1 — associated with more favorable prognosis
  • ASXL1, EZH2, RUNX1 — associated with poor prognosis
  • TET2, DNMT3A — common mutations with variable significance
  • Other genes like SRSF2, U2AF1, and ZRSR2

4. Blood Counts

• Hemoglobin (red blood cells)
• Platelet count
• Neutrophil count (white blood cells)

What Does Your Grade Mean?

Lower-Risk MDS (Very-Low, Low, Intermediate):

• Disease progresses more slowly
• Median survival is typically measured in years
• Focus is on managing symptoms and monitoring closely
• Treatment may include supportive care, growth factors, or targeted therapies

Higher-Risk MDS (High, Very-High):

• Disease may progress more quickly toward acute myeloid leukemia (AML)
• Median survival is typically shorter
• More aggressive treatment approaches are usually recommended
• May include hypomethylating agents (like azacitidine or decitabine) or stem cell transplant

Important Context

According to NCCN Guidelines, no single factor determines your grade — it's the combination of all these factors that creates your risk score. This is why your doctor may discuss multiple test results together rather than focusing on just one number.

Also important: Your grade doesn't define your outcome. Individual responses to treatment vary significantly. Some patients with higher-risk disease respond very well to treatment, while others with lower-risk disease may need more intensive management.

Questions to Ask Your Doctor

1. What is my specific IPSS-R risk category, and what does that mean for my prognosis?
2. Which factors (blasts, cytogenetics, mutations) are most important in my case?
3. How will my grade affect my treatment plan?
4. How often will my grade be reassessed, and what would cause it to change?
5. Are there any clinical trials appropriate for my risk category?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.